Senti Biosciences (SNTI) Expected to Post Earnings on Thursday

Senti Biosciences (NASDAQ:SNTI) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Senti Biosciences to announce earnings of ($0.33) per share and revenue of $0.0150 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.22. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. On average, analysts expect Senti Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Senti Biosciences Trading Up 8.7%

NASDAQ:SNTI opened at $0.37 on Tuesday. The stock has a 50 day simple moving average of $0.84 and a 200 day simple moving average of $0.91. The stock has a market cap of $11.53 million, a P/E ratio of -0.19 and a beta of 2.11. Senti Biosciences has a 1-year low of $0.34 and a 1-year high of $2.88.

Analyst Ratings Changes

Several research analysts have weighed in on SNTI shares. Chardan Capital increased their price objective on Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Investors Weigh In On Senti Biosciences

Institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new stake in shares of Senti Biosciences during the 2nd quarter worth $1,883,000. Geode Capital Management LLC lifted its position in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the period. Citadel Advisors LLC bought a new stake in Senti Biosciences during the third quarter worth about $117,000. Virtu Financial LLC acquired a new stake in Senti Biosciences during the fourth quarter worth about $46,000. Finally, Jane Street Group LLC acquired a new stake in Senti Biosciences during the fourth quarter worth about $40,000. 25.70% of the stock is currently owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.